Trial Profile
Genetic and clinical predictors of treatment response in depression.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs Citalopram (Primary) ; Reboxetine (Primary)
- Indications Major depressive disorder
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms GENPOD
- 22 Dec 2011 Results published in the British Journal of Psychiatry.
- 22 May 2008 Results are expected to be reported in September 2008, according to the study protocol published in Trials.
- 24 Oct 2006 New trial record.